SCHEMBL6819956

SCHEMBL6819956

CC/C(=C/c1ccc(OCc2ccccc2)c(C(C)(C)C)c1)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.48
RXRB P28702 1/20 0.48
RXRG P48443 1/20 0.48
LTB4R Q15722 1/20 0.47
LTB4R2 Q9NPC1 1/20 0.47
KDM4E B2RXH2 3/20 0.46
LMNA P02545 1/20 0.46
ALDH1A1 P00352 4/20 0.44
HPGD P15428 3/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
PSEN1 P49768 4/20 0.43
ALOX5 P09917 2/20 0.43
PTGES O14684 1/20 0.43
PPARG P37231 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
POLB P06746 1/20 0.43
APP P05067 4/20 0.43
PSEN2 P49810 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6816293 0.84 FFAR4 (0.56) RXRARXRBRXRGLTB4RLTB4R2
SCHEMBL6819961 0.84 KDM4E (0.47) RXRARXRBRXRGKDM4ELMNA
SCHEMBL6819952 0.84 KDM4E (0.47) RXRARXRBRXRGKDM4ELMNA
SCHEMBL3235715 0.80 MAOA (0.52) RXRARXRBRXRGKDM4ELMNA
SCHEMBL6819041 0.80 CTSV (0.53) LTB4RLTB4R2KDM4ELMNAALDH1A1
SCHEMBL3978528 0.77 NR1H4 (0.64) KDM4ELMNAALDH1A1NPC1RAB9A
SCHEMBL3550674 0.77 KDM4E (0.60) LTB4RLTB4R2KDM4ELMNAALDH1A1
SCHEMBL3550677 0.77 KDM4E (0.60) LTB4RLTB4R2KDM4ELMNAALDH1A1
SCHEMBL5030365 0.75 RXRA (0.72) RXRARXRBRXRG
SCHEMBL3636855 0.74 MAPT (0.57) KDM4ELMNAALDH1A1HPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6750252-B2 FOR USE IN CLINICAL CONDITIONS ASSOCIATED WITH INSULIN RESISTANCE ASTRAZENECA AB (SE) 2004-06-15 US disclosed
EP-1237856-B1 NEW TRI-SUBSTITUTED PHENYL DERIVATIVES AND ANALOGUES ASTRAZENECA AB (SE) 2004-05-12 EP disclosed
US-20030149104-A1 Tri-substituted phenyl derivatives and analogues ASTRAZENECA AB (SE) 2003-08-07 US disclosed
EP-1237856-A1 NEW TRI-SUBSTITUTED PHENYL DERIVATIVES AND ANALOGUES AstraZeneca AB (SE) 2002-09-11 EP disclosed
WO-2001040172-A1 NEW TRI-SUBSTITUTED PHENYL DERIVATIVES AND ANALOGUES ASTRAZENECA AB (SE) 2001-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149104-A1 Tri-substituted phenyl derivatives and analogues GPR119, IAPP, INSR RXRA 825/4885RXRB 570/4885RXRG 664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.